Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 17/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 17/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590117 | 0.81 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL28032981 | 0.79 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL30216514 | 0.79 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL156023 | 0.79 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL2795502 | 0.76 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL2162196 | 0.76 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1AKR1C4 | |
| SCHEMBL4611439 | 0.75 | HDAC1 (0.44) | AKR1C3AKR1C2AKR1C1PTGS1AKR1C4 | |
| SCHEMBL20943248 | 0.75 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL10918668 | 0.74 | AKR1C3 (0.42) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL9606829 | 0.73 | MMP8 (0.41) | AKR1C3AKR1C2PTGS1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | AKR1C3 411/4885AKR1C2 598/4885AKR1C1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.